American Healthcare REIT (AHR)

NYSEReal EstateReit - Healthcare FacilitiesSnapshot 2026-10-23

$53.02-0.71%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge American Healthcare REIT’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	744.24M
EPS	—	0.155
FY 2026 · Annual
Revenue	—	2.81B
EPS	$0.54–$0.58	0.595
FFO per share	$2.04–$2.08	—
FY 2027 · Annual
Revenue	—	3.15B
EPS	—	0.779

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Normalized Funds From Operations per diluted share of at least $2.03 in FY26	It raised normalized funds from operations per share guidance to $2.03 to $2.09.	Intact	NFFO per diluted share falls below $2.03 in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Full-year 2026 NFFO per diluted share guidance midpoint increased from $2.06 in 2026-Q1 to $2.17 in 2026-Q2, representing over 5% growth. Management has consistently raised guidance, indicating delivery and positive trajectory. Delivery assessment Oct 24, 2026
Quarterly dividend maintained at $0.25 per share	The company keeps paying a steady $0.25 quarterly dividend.	Intact	Dividend per share falls below $0.25 in any quarter of 2026	Dividend per share: $0.25 per share FY2026-Q2; GAAP. Published target: >=0.25 USD per share. The target does not explicitly identify fiscal versus calendar quarters. Source published Aug 7, 20260.25 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: a29d66e0-e37f-4c6b-b1a7-f20ac07f864e. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. The Company consistently declared and paid a quarterly distribution of $0.25 per share in 2026-Q1, Q2, and Q3, demonstrating stable capital return to shareholders. Delivery assessment Oct 24, 2026
Same-Store Net Operating Income growth of at least 9% in FY26	American Healthcare REIT grows same-store NOI about 9% to 12% in 2026.	Intact	Same-Store NOI growth falls below 9.0% in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Total portfolio Same-Store NOI growth rose from 11.8% in 2025-Q4 to 13.2% in 2026-Q2. Management has consistently increased full-year guidance from 7.0%-11.0% to 11.0%-13.0%, reflecting delivery and upward trajectory. Delivery assessment Oct 24, 2026
Senior Housing Operating Properties acquisitions of at least $160 million in Q1 2026	It expands its senior housing portfolio with over $160 million in recent acquisitions.	Intact	SHOP acquisitions fall below $160 million in Q1 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 4 quarters. Management completed SHOP acquisitions of approximately $590 million in 2025, $162.8 million in 2026-Q1, and $126.9 million in 2026-Q2, demonstrating ongoing execution and expansion of the segment. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue$3.15B

$3.05B → $3.15B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$3,054,086,970	2 / 6
2026-07-25	Unavailable	$3,054,086,970	2 / 6
2026-07-26	Unavailable	$3,054,086,970	2 / 6
2026-07-27	Unavailable	$3,054,086,970	2 / 6
2026-07-28	Unavailable	$3,054,086,970	2 / 6
2026-07-29	Unavailable	$3,054,086,970	2 / 6
2026-07-30	Unavailable	$3,054,086,970	2 / 6
2026-07-31	Unavailable	Unavailable	3 / 4
2026-08-01	Unavailable	$3,054,086,970	2 / 6
2026-08-02	Unavailable	$3,054,086,970	2 / 6
2026-08-03	Unavailable	$3,054,086,970	2 / 6
2026-08-04	Unavailable	$3,054,086,970	2 / 6
2026-08-05	Unavailable	$3,054,086,970	2 / 6
2026-08-06	Unavailable	$3,054,086,970	2 / 6
2026-08-07	Unavailable	$3,054,086,970	2 / 6
2026-08-08	Unavailable	$3,054,086,970	2 / 6
2026-08-09	Unavailable	$3,054,086,970	2 / 6
2026-08-10	Unavailable	$3,054,086,970	2 / 6
2026-08-11	Unavailable	$3,006,557,560	2 / 5
2026-08-12	Unavailable	$3,024,937,560	1 / 5
2026-08-13	Unavailable	$3,024,937,560	1 / 5
2026-08-14	Unavailable	Unavailable	3 / 4
2026-08-15	Unavailable	Unavailable	3 / 4
2026-08-16	Unavailable	Unavailable	3 / 4
2026-08-17	Unavailable	Unavailable	3 / 4
2026-08-18	Unavailable	Unavailable	3 / 4
2026-08-19	Unavailable	$2,908,339,722	3 / 5
2026-08-20	Unavailable	$2,908,339,722	3 / 5
2026-08-21	Unavailable	$3,082,052,980	3 / 5
2026-08-22	Unavailable	$3,082,052,980	3 / 5
2026-08-23	Unavailable	$3,082,052,980	3 / 5
2026-08-24	Unavailable	$3,082,052,980	3 / 5
2026-08-25	Unavailable	$3,082,052,980	3 / 5
2026-08-26	Unavailable	$3,082,052,980	3 / 5
2026-08-27	Unavailable	$3,082,052,980	3 / 5
2026-08-28	Unavailable	$3,082,052,980	3 / 5
2026-08-29	Unavailable	$3,082,052,980	3 / 5
2026-08-30	Unavailable	$3,082,052,980	3 / 5
2026-08-31	Unavailable	$3,082,052,980	3 / 5
2026-09-01	Unavailable	$3,082,052,980	3 / 5
2026-09-02	Unavailable	$3,082,052,980	3 / 5
2026-09-03	Unavailable	$3,083,651,998	3 / 5
2026-09-04	Unavailable	$3,083,651,998	3 / 5
2026-09-05	Unavailable	$3,083,651,998	3 / 5
2026-09-06	Unavailable	$3,083,651,998	3 / 5
2026-09-07	Unavailable	$3,083,651,998	3 / 5
2026-09-08	Unavailable	$3,083,651,998	3 / 5
2026-09-09	Unavailable	$3,083,651,998	3 / 5
2026-09-10	Unavailable	$3,083,651,998	3 / 5
2026-09-11	Unavailable	$3,083,651,998	3 / 5
2026-09-12	Unavailable	$3,083,651,998	3 / 5
2026-09-13	Unavailable	$3,083,655,998	3 / 5
2026-09-14	Unavailable	$3,083,655,998	3 / 5
2026-09-15	Unavailable	$3,097,983,270	3 / 5
2026-09-16	Unavailable	$3,097,983,270	3 / 5
2026-09-17	Unavailable	$3,097,983,270	3 / 5
2026-09-18	Unavailable	$3,097,983,270	3 / 5
2026-09-19	Unavailable	$3,097,983,270	3 / 5
2026-09-20	Unavailable	$3,098,521,425	3 / 5
2026-09-21	Unavailable	$3,098,521,425	3 / 5
2026-09-22	Unavailable	$3,098,521,425	3 / 5
2026-09-23	Unavailable	$3,098,521,425	3 / 5
2026-09-24	Unavailable	$3,098,521,425	3 / 5
2026-09-25	Unavailable	$3,098,521,425	3 / 5
2026-09-26	Unavailable	$3,098,521,425	3 / 5
2026-09-27	Unavailable	$3,098,521,425	3 / 5
2026-09-28	Unavailable	$3,098,521,425	3 / 5
2026-09-29	Unavailable	$3,098,521,425	3 / 5
2026-09-30	Unavailable	$3,098,521,425	3 / 5
2026-10-01	Unavailable	$3,098,521,425	3 / 5
2026-10-02	Unavailable	$3,100,526,095	3 / 5
2026-10-03	Unavailable	$3,100,495,604	3 / 5
2026-10-04	Unavailable	$3,100,495,604	3 / 5
2026-10-05	Unavailable	$3,100,495,604	3 / 5
2026-10-06	Unavailable	$3,100,526,095	3 / 5
2026-10-07	Unavailable	$3,100,526,095	3 / 5
2026-10-08	Unavailable	$3,100,526,095	3 / 5
2026-10-09	Unavailable	$3,100,526,095	3 / 5
2026-10-10	Unavailable	$3,100,526,095	3 / 5
2026-10-11	Unavailable	$3,100,526,095	3 / 5
2026-10-12	Unavailable	$3,100,526,095	3 / 5
2026-10-13	Unavailable	Unavailable	3 / 4
2026-10-14	Unavailable	Unavailable	3 / 4
2026-10-15	Unavailable	Unavailable	3 / 4
2026-10-16	Unavailable	$3,151,090,587	3 / 5
2026-10-17	Unavailable	$3,151,090,587	3 / 5
2026-10-18	Unavailable	$3,151,090,587	3 / 5
2026-10-19	Unavailable	$3,151,090,587	3 / 5
2026-10-20	Unavailable	$3,151,090,587	3 / 5
2026-10-21	Unavailable	$3,151,090,587	3 / 5
2026-10-22	Unavailable	$3,151,090,587	3 / 5
2026-10-23	Unavailable	$3,151,090,587	3 / 5
2026-10-24	Unavailable	$3,151,090,587	3 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	12	1
2026-06-01	13	1
2026-07-01	15	0
2026-08-01	15	0
2026-09-01	15	0
2026-10-01	16	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 16 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades2 maintains

Recent actions · Sep 25–Oct 24 · 2 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Raymond JamesOct 13

$62.00New observation · no comparable prior

BarclaysOct 13 · prior Aug 31

$66.00 → $60.00-9.1%

$0$36.30$72.60

0 raises · 1 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Normalized Funds From Operations per diluted share of at least $2.03 in FY26Direct metric needs a verified mapping
Quarterly dividend maintained at $0.25 per shareDividend per share: $0.25 per share
Same-Store Net Operating Income growth of at least 9% in FY26Direct metric needs a verified mapping
Senior Housing Operating Properties acquisitions of at least $160 million in Q1 2026Direct metric needs a verified mapping

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.0%Typical daily move · historical

Downside history

-14.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

American Healthcare REIT outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

AHR is a real estate growth and execution story, rather than a proven durable compounder, because the company is loss-making and management execution is rated volatile. The long-term thesis is intact, with recent financial performance strong, but evidence is mixed on some stated priorities.

What's priced into American Healthcare REIT

AHR is expensive versus peers, with a 2.09 premium measure, and the valuation case depends on a re-rating, meaning the market assigning a higher valuation. The expectations gap is negative at -0.17, but model confidence is low, so the evidence on what the market already assumes is limited.

What the fundamentals likely do

Near-term operating momentum has improved, and management raised full-year guidance, including the NFFO per-share midpoint to $2.17 and Same-Store NOI growth guidance to 11.0%-13.0%. Guidance reversals, a recent history of misses, a CFO transition, and a sector headwind remain risks; the snapshot rates near-term miss risk as quiet, with a 34% estimate.

What American Healthcare REIT hinges on

The multi-year case depends on continued growth in Same-Store NOI and NFFO, while SHOP acquisitions add scale without weakening execution. Near-term signals include whether management preserves its raised guidance, whether the Fed begins cutting rates from 3.88%, and whether sector peers keep reporting strong results and raising guidance.